Recombinant Vaccine

What are the Components of Recombinant Vaccines?

Expression Systems

The creation of recombinant vaccines requires multiple expression systems to function effectively.

• Bacterial System (e.g., Escherichia coli): The bacterial system combines rapid growth with low production expenses while failing to perform essential post-translational modifications. The rapid growth rate and extensive molecular manipulation capabilities render E. coli a top choice for recombinant protein production. The Lyme disease vaccine approved by FDA contains recombinant outer surface proteins created through E. coli production techniques.
• Yeast System (e.g., Saccharomyces cerevisiae): Its ability to execute partial post-translational modifications qualifies this system for manufacturing complex antigens. Researchers widely use the yeast system because it grows quickly and allows straightforward genetic modifications. Yeast cells have the ability to release recombinant proteins which makes subsequent purification steps easier.
• Mammalian Cell System (e.g., CHO cells): Mammalian cell systems generate nearly natural post-translational modifications yet come with increased financial expenses. The production of recombinant vaccines depends on mammalian cell systems because they produce glycoproteins with natural structural and post-translational modifications.
• Insect Cell System (e.g., Baculovirus system): Suitable for producing complex glycosylated antigens. Despite high production expenses, the insect cell system remains a popular choice for expressing complex glycosylated antigens.

Antigen Genes

The core component of recombinant vaccines consists of selected key antigen genes from pathogens including the spike protein (S protein) of SARS-CoV-2. Through stability optimization of the S protein its immunogenicity receives enhancement. The S protein consists of S1 and S2 subunits while the S1 subunit contains the receptor-binding domain (RBD) that binds to the ACE-2 receptor on host cells. Adjusting the RBD creates a stronger immune reaction from the vaccine.

Adjuvants

The use of adjuvants like alum, MF59 or CpG is generally necessary to enhance the efficacy of recombinant vaccines. to enhance immune responses. MF59 boosts antigen-specific CD4+ T cell responses by emulsifying the oil and water phases. The choice and refinement of adjuvants play a crucial role in boosting vaccine immune effects.

Advantages and Disadvantages of Recombinant Vaccines

Advantages

• High Safety: These vaccines do not carry an infection risk making them ideal for people with weakened immune systems. Recombinant vaccines provide advanced protection against complicated diseases like HIV through enhanced safety measures.
• Controlled Production Process: These products can be quickly expanded to meet large-scale production needs and serve as an excellent tool in public health crisis situations. The swift manufacturing and distribution of recombinant vaccines greatly expanded vaccine access worldwide during the COVID-19 pandemic.
• Targeted Design: They can be engineered to target particular antigens which improves vaccine specificity. The immune response to SARS-CoV-2 gets effectively triggered through recombinant vaccines that optimize the S protein.

Disadvantages

• May Require Adjuvants: Recombinant vaccines display low immunogenicity that requires the addition of adjuvants to enhance immune responses. Vaccine performance experiences substantial improvements when MF59 and CpG adjuvants are incorporated.
• Limited Effectiveness for Some Pathogens: Traditional vaccines show better effectiveness than recombinant vaccines when creating treatments for complex diseases like HIV. Extensive genetic variation and rapid mutation of HIV form significant barriers for developing recombinant vaccines.